Achieve Life Sciences, Inc. financial data

Symbol
ACHV on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
22722 29 Th Dr. Se, Suite 100, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ONCOGENEX PHARMACEUTICALS, INC. (to 7/31/2017), SONUS PHARMACEUTICALS INC (to 8/7/2008)
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 445 % +159%
Debt-to-equity 53.7 % -91.5%
Return On Equity -111 % +88.2%
Return On Assets -72 % +43.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.7M shares +1.27%
Common Stock, Shares, Outstanding 34.7M shares +63.9%
Entity Public Float 144M USD +58.8%
Common Stock, Value, Issued 103K USD +14.4%
Weighted Average Number of Shares Outstanding, Basic 32.1M shares +61.8%
Weighted Average Number of Shares Outstanding, Diluted 32.1M shares +61.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22.8M USD +44.3%
General and Administrative Expense 16.3M USD +42.1%
Costs and Expenses 39.1M USD +43.4%
Nonoperating Income (Expense) -758K USD +70.4%
Net Income (Loss) Attributable to Parent -39.8M USD -33.6%
Earnings Per Share, Basic -1.24 USD/shares +17.3%
Earnings Per Share, Diluted -1.24 USD/shares +17.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.8M USD -18%
Marketable Securities, Current 21.6M USD
Cash, Cash Equivalents, and Short-term Investments 34.4M USD
Assets, Current 36.5M USD +115%
Property, Plant and Equipment, Net 8K USD -38.5%
Operating Lease, Right-of-Use Asset 119K USD +80.3%
Goodwill 1.03M USD 0%
Assets 38.6M USD +99.4%
Accounts Payable, Current 1.95M USD +216%
Employee-related Liabilities, Current 3.03M USD +31%
Liabilities, Current 6.68M USD -67.9%
Operating Lease, Liability, Noncurrent 66K USD +1000%
Liabilities 17.7M USD -14.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 31K USD +675%
Retained Earnings (Accumulated Deficit) -206M USD -24%
Stockholders' Equity Attributable to Parent 20.9M USD
Liabilities and Equity 38.6M USD +99.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.29M USD +36.3%
Net Cash Provided by (Used in) Financing Activities 56.1M USD +119283%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 34.7M shares +63.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.8M USD
Deferred Tax Assets, Valuation Allowance 81.8M USD +11.7%
Deferred Tax Assets, Gross 82.2M USD +11.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.4M USD -74.9%
Property, Plant and Equipment, Gross 256K USD 0%
Operating Lease, Liability, Current 55K USD -12.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 54.6M USD +11.6%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 761K USD 0%
Operating Lease, Payments 59K USD +3.51%
Amortization of Intangible Assets 200K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 330K USD -4.62%
Interest Expense 2.77M USD +6.01%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%